Filing Analysis
Aligos Therapeutics, Inc. filed an 8-K to announce the release of a press release regarding its results of operations and financial condition as of August 6, 2026.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- A press release was issued on August 6, 2026, which is incorporated by reference as Exhibit 99.1.
- The report was signed by Lesley Ann Calhoun, EVP, COO, and CFO.
Aligos Therapeutics held its Annual Meeting of Stockholders on June 25, 2026, where shareholders approved several key proposals including the election of two directors and an amendment to the Employee Stock Purchase Plan (ESPP). The ESPP amendment increases the share reserve by 500,000 shares but eliminates the automatic 'evergreen' increase provision.
🚩 Red Flags
- Elimination of the ESPP evergreen provision suggests a move to limit future dilution, which is generally positive for existing shareholders but indicates a shift in capital allocation strategy.
📋 Key Facts
- Annual Meeting held on June 25, 2026.
- Stockholders approved an amendment to the 2020 Employee Stock Purchase Plan (ESPP).
- The ESPP Amendment reserves an additional 500,000 shares for issuance.
- The 'evergreen' provision in the ESPP was eliminated; share reserve is now a fixed number without automatic annual increases.
- Bridget Martell and Carole Nuechterlein were elected as Class III directors.
- Ernst & Young LLP was ratified as the independent auditor for fiscal year 2026.
- Shareholders approved 'Say-on-Pay' (executive compensation) on a non-binding, advisory basis.
Aligos Therapeutics, Inc. reported its financial results for the period ending May 7, 2026. The filing serves as a routine disclosure of the company's results of operations and financial condition via a furnished press release.
📋 Key Facts
- The report was filed on May 7, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was included as Exhibit 99.1.
- The filing was signed by Lesley Ann Calhoun, who serves as Executive Vice President, Chief Operating Officer, and Chief Financial Officer.
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Aligos Therapeutics entered into an exclusive license agreement with Xiamen Amoytop Biotech for the development and commercialization of pevifoscorvir sodium in Greater China. The deal provides Aligos with a $25 million upfront payment and eligibility for up to $420 million in future milestones plus royalties.
🚩 Red Flags
- The agreement is not yet effective and will terminate automatically if Amoytop shareholders do not approve the transaction within 45 days of execution.
- The license is restricted to a specific geographic territory (Greater China), leaving Aligos responsible for other major markets.
📋 Key Facts
- Agreement signed on April 16, 2026, with Xiamen Amoytop Biotech Co., Ltd.
- Aligos receives a $25 million upfront cash payment.
- Potential development, regulatory, and commercial milestones total up to $420 million.
- Tiered, high single-digit royalties on net sales in mainland China, Taiwan, Hong Kong, and Macau.
- Amoytop assumes all costs for development, regulatory activities, and manufacturing within the licensed territory.
- The agreement is contingent upon Amoytop shareholder approval, expected within 30 days and required within 45 days.
Aligos Therapeutics announced that its Phase 2 B-SUPREME study for pevifoscorvir sodium will continue following a DSMB review, which recommended increasing the sample size for the HBeAg- cohort. Additionally, the FDA has granted Fast Track Designation to pevifoscorvir sodium for the treatment of chronic hepatitis B virus (HBV) infection.
🚩 Red Flags
- The requirement to increase sample size for 'statistical powering' may indicate that the observed effect size was lower than initially projected, potentially leading to increased R&D costs and extended trial timelines.
📋 Key Facts
- The independent Data Safety Monitoring Review Board (DSMB) recommended the continuation of the Phase 2 B-SUPREME study.
- The DSMB recommended an increase in sample size for the Part 2a (HBeAg- cohort) to optimize statistical powering.
- Futility criteria for the HBeAg- cohort was not met during the first interim analysis.
- The FDA granted Fast Track Designation to pevifoscorvir sodium, a capsid assembly modulator (CAM-E).
- The drug is being investigated for the treatment of chronic HBV infection.
Aligos Therapeutics issued a press release on March 5, 2026, announcing its financial results and operations condition. The filing is a standard disclosure of periodic financial performance.
📋 Key Facts
- Date of report: March 5, 2026
- Disclosed under Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 contains the full press release
- Signed by Lesley Ann Calhoun, EVP, COO, and CFO
Aligos Therapeutics announced a leadership reorganization within its finance department. Nikhil Aneja has been appointed as Principal Accounting Officer, succeeding Lesley Ann Calhoun in that specific capacity.
📋 Key Facts
- Nikhil Aneja appointed as Principal Accounting Officer effective January 29, 2026.
- Lesley Ann Calhoun transitions from the PAO role to focus on her roles as EVP, COO & CFO.
- Mr. Aneja previously served as VP of Finance at Aligos since February 2024.
- Mr. Aneja is a Certified Public Accountant with prior leadership experience at CareDx, Inc., Blade Therapeutics, and Global Blood Therapeutics.
Aligos Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition as of November 6, 2025.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- A press release was issued on November 6, 2025, which is incorporated by reference as Exhibit 99.1.
- The company is an emerging growth company.
Aligos Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition as of August 6, 2025.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- A press release was issued on August 6, 2025, which is incorporated by reference as Exhibit 99.1.
- The company is an emerging growth company.
Aligos Therapeutics held its Annual Meeting of Stockholders on June 25, 2025, where shareholders approved significant increases to authorized share counts and the company's equity incentive plan. These changes provide substantial headroom for future dilutive events, including stock issuances and employee compensation.
🚩 Red Flags
- Massive increase in authorized voting common stock (from 20M to 100M shares), indicating significant potential for future dilution through secondary offerings.
- Increase in equity incentive plan reserves provides more capacity for dilutive compensation-based issuances.
📋 Key Facts
- Stockholders approved an amendment to the 2020 Incentive Award Plan to increase reserved shares by 1,000,000 shares.
- Stockholders approved an amendment to the Certificate of Incorporation to increase authorized voting common stock from 20,000,000 to 100,000,000 shares.
- Stockholders approved an amendment to increase non-voting common stock from 800,000 to 15,800,000 shares.
- The company ratified Ernst & Young LLP as the independent auditor for fiscal year 2025.
- Three Class II directors (K. Peter Hirth, Heather Preston, and Margarita Chavez) were elected.
Aligos Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition. The filing serves as a formal mechanism to furnish recent financial updates to the market.
📋 Key Facts
- The company issued a press release on May 6, 2025, regarding results of operations and financial condition (Item 2.02).
- The registrant is an emerging growth company as defined by the SEC.
- The filing was signed by Lesley Ann Calhoun, EVP, COO, and CFO.
Aligos Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition as of March 10, 2025.
📋 Key Facts
- The filing is primarily used to furnish a press release (Exhibit 99.1) containing financial information.
- The report was filed on March 10, 2025.
- The company is an emerging growth company.
Aligos Therapeutics announced a $105 million private placement of common stock, pre-funded warrants, and accompanying warrants. The deal includes significant registration rights and board nomination rights for the lead investor.
🚩 Red Flags
- Significant dilution potential due to the large number of warrants and shares issuable upon exercise.
- The company is prohibited from issuing additional equity until a registration statement is effective or 60 days after closing, indicating tight liquidity management.
- Warrants have long expiration dates (2032), creating long-term overhang on the stock price.
📋 Key Facts
- Total gross proceeds from the Private Placement are approximately $105 million.
- Securities include 2,103,307 shares of common stock (voting and non-voting), pre-funded warrants for up to 1,922,511 shares, and accompanying warrants for up to 2,012,909 shares.
- The combined price per share/warrant unit is approximately $26.08.
- Closing of the transaction is expected on February 13, 2025.
- Lead Investor (Baker Brothers Life Sciences, L.P.) has rights to nominate up to two individuals to the Board of Directors subject to ownership thresholds.
Aligos Therapeutics, Inc. announced the appointment of Lesley Ann Calhoun as Chief Operating Officer (COO), effective January 30, 2025. Ms. Calhoun will retain her existing responsibilities as Chief Financial Officer (CFO).
📋 Key Facts
- Lesley Ann Calhoun appointed as COO effective January 30, 2025.
- Ms. Calhoun retains her current role as CFO.
- Ms. Calhoun has served as EVP and CFO of Aligos since June 2020.
- Ms. Calhoun's background includes roles at Tango Therapeutics, Global Blood Therapeutics, Hyperion Therapeutics (acquired by Horizon Pharma), and Innoviva.
Aligos Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition for the period ending November 6, 2024.
📋 Key Facts
- The filing is primarily used to furnish a press release (Exhibit 99.1) containing financial updates.
- The report was filed on November 6, 2024.
- The company is an emerging growth company.
Aligos Therapeutics has regained compliance with Nasdaq's minimum bid price requirement. The company successfully resolved the deficiency that had been under review since September 2023.
🚩 Red Flags
- Historical non-compliance with Nasdaq's minimum bid price requirement (though now resolved).
📋 Key Facts
- On September 3, 2024, Nasdaq notified the Company it has regained compliance with Minimum Bid Price Requirements (Nasdaq Listing Rules 5450(a)(1) and 5550(a)(2)).
- The matter regarding the minimum bid price is now considered closed.
- The deficiency originated from a failure to maintain a $1.00 minimum bid price for 30 consecutive business days, as noted in a previous letter dated September 5, 2023.
Aligos Therapeutics, Inc. has implemented a 1-for-25 reverse stock split effective August 19, 2024. The action was taken primarily to regain compliance with the Nasdaq Capital Market's minimum bid price requirements.
🚩 Red Flags
- Reverse stock split (often a sign of extreme share price depreciation)
- Delisting risk/Compliance necessity (explicitly stated as the primary reason for the split)
📋 Key Facts
- Reverse split ratio: 1-for-25
- Effective date: August 19, 2024, at 12:01 a.m. ET
- Purpose: To comply with Nasdaq minimum required closing bid price for continued listing
- No fractional shares will be issued; stockholders will receive cash in lieu of fractions based on the Aug 16, 2024, closing price
- New CUSIP number: 01626L 204
- The split does not modify rights or preferences of common stock
Aligos Therapeutics expanded its Board of Directors from five to seven members. The company appointed Heather Preston, M.D., and Margarita Chavez, J.D., as new Class II directors.
📋 Key Facts
- Board size increased from 5 to 7 authorized directors.
- Heather Preston, M.D., appointed as a Director and Chair of the Nominating Committee.
- Margarita Chavez, J.D., appointed as a Director and member of the Audit Committee.
- Dr. Preston to receive $40,000 annual retainer plus $8,000 for committee chair role, and 120,000 stock options.
- Ms. Chavez to receive $40,000 annual retainer plus $7,500 for Audit Committee service.
- Both appointees are non-employee directors under the 2020 Incentive Award Plan.
Aligos Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition as of August 6, 2024.
📋 Key Facts
- The filing is primarily used to furnish a press release (Exhibit 99.1) containing financial results.
- Report date: August 6, 2024.
- The company is an emerging growth company.
Aligos Therapeutics held its Annual Meeting of Stockholders on June 27, 2024, where shareholders approved several key items including an increase in authorized shares and a mandate for the Board to execute a reverse stock split if deemed necessary.
🚩 Red Flags
- Approval of a reverse stock split mandate (Proposal 3) is a significant red flag often used to maintain Nasdaq listing compliance or combat low share prices.
- Significant increase in authorized shares (from 300M to 500M) suggests potential future dilution via equity offerings.
📋 Key Facts
- Shareholders approved Proposal 3: Granting authority to the Board to effect a reverse stock split if deemed in the company's best interest.
- Shareholders approved Proposal 5: Increasing authorized voting common stock from 300,000,000 to 500,000,000 shares.
- Shareholders approved an amendment to the 2020 Incentive Award Plan regarding the treatment of pre-funded warrants (Proposal 4).
- Ratification of Ernst & Young LLP as independent auditors for fiscal year ending Dec 31, 2024 was approved.
- Two Class I directors were elected: Lawrence M. Blatt and James Scopa.
Aligos Therapeutics received a notification from Nasdaq regarding noncompliance with Listing Rule 5605 due to insufficient independent directors on the Audit Committee following Jack Nielsen's resignation. The company has been granted a cure period and intends to appoint a third independent director to regain compliance.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq listing rules.
- Governance deficiency resulting from an officer/director departure (Jack Nielsen).
📋 Key Facts
- Received Nasdaq notification letter on May 29, 2024, regarding noncompliance with Rule 5605.
- Noncompliance stems from the resignation of Jack Nielsen effective May 21, 2024.
- The Audit Committee currently lacks the required minimum of three independent directors.
- Cure period expires on November 18, 2024 (based on the upcoming June 27, 2024 annual meeting).
- Company plans to appoint a third independent director to resolve the deficiency.
Aligos Therapeutics notified Nasdaq of non-compliance with listing rules following the resignation of board member Jack Nielsen. The vacancy in the Audit Committee has left the committee with only two members, violating Nasdaq Rule 5605(c)(2)(A).
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules.
- Audit Committee vacancy creates regulatory risk if not remediated within the cure period.
📋 Key Facts
- Jack Nielsen resigned from the Board effective May 21, 2024.
- The resignation created a vacancy on the Audit Committee, leaving it with only two members.
- The company is in non-compliance with Nasdaq Rule 5605(c)(2)(A) regarding Audit Committee composition.
- The company notified Nasdaq of its intent to rely on a cure period under Nasdaq Rule 5605(c)(4)(B).
- The company must appoint a third qualified director to the Audit Committee within 180 days.
Aligos Therapeutics, Inc. announced the resignation of its Chief Medical Officer, Matthew McClure, effective May 9, 2024.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a clinical-stage biotech company can disrupt R&D timelines and clinical trial management.
📋 Key Facts
- Matthew McClure resigned from his position as Chief Medical Officer on May 9, 2024.
- The resignation was communicated to the Company by Mr. McClure.
Aligos Therapeutics, Inc. filed an 8-K to furnish a press release regarding its results of operations and financial condition for the period ending May 7, 2024.
📋 Key Facts
- The filing is primarily used to incorporate Exhibit 99.1 (Press Release) by reference.
- The report was signed by Lesley Ann Calhoun, EVP and CFO on May 7, 2024.
- The company is classified as an 'emerging growth company'.
Aligos Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its results of operations and financial condition for the period ending March 12, 2024.
📋 Key Facts
- The filing is primarily used to furnish a press release (Exhibit 99.1) containing financial results.
- Report date: March 12, 2024.
- The company is classified as an 'emerging growth company'.
Aligos Therapeutics completed a one-time stock option exchange program to address underwater options. The program resulted in the cancellation of 3,880,332 shares and the issuance of 1,906,153 replacement options at varying exchange ratios.
🚩 Red Flags
- Significant dilution/restructuring of equity incentive plan due to 'underwater' options.
- The exchange ratios (1.4:1 and 3.4:1) function as a de facto reverse stock split for option holders to bring strike prices closer to market value.
- High percentage of participation (93%) indicates widespread failure of previous equity incentives to track share price.
📋 Key Facts
- Option Exchange expired on February 27, 2024.
- Total shares surrendered for exchange: 3,880,332 (approx. 93% of eligible options).
- Replacement options issued: 1,906,153 shares under the 2020 Incentive Award Plan.
- Exchange ratios were applied on a grant-by-grant basis at 1.4-for-1 or 3.4-for-1.
- All surrendered options had exercise prices significantly above recent trading prices (underwater).
- Replacement options carry a new one-year initial vesting period.
Aligos Therapeutics announced a voluntary one-time option exchange program for eligible employees and directors. The program allows participants to exchange existing options (with exercise prices ≥ $2.10) for replacement options covering fewer shares under a new vesting schedule.
🚩 Red Flags
- Option exchanges/re-pricing often indicate that existing options are significantly out-of-the-money, suggesting recent downward pressure on the stock price.
📋 Key Facts
- Announcement date: January 25, 2024
- Program type: Voluntary one-time option exchange program
- Eligible participants: Certain employees and board members resident in the US or Switzerland
- Eligibility criteria: Options granted under the 2020 Incentive Award Plan with an exercise price ≥ $2.10
- Terms: Replacement options will cover a lesser number of shares based on specified exchange ratios and include a new vesting schedule
- Status: Terms are being finalized; formal Tender Offer Statement (Schedule TO) to follow